These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21848524)

  • 1. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
    Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
    Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
    Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making advances in first-line chronic lymphocytic leukemia treatment.
    Wierda WG
    J Clin Oncol; 2012 Sep; 30(26):3162-4. PubMed ID: 22869876
    [No Abstract]   [Full Text] [Related]  

  • 4. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
    Friedberg JW
    Leuk Lymphoma; 2009 Sep; 50(9):1399-400. PubMed ID: 19811324
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chronic lymphocytic leukemia].
    Aoki S
    Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
    García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
    Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
    [No Abstract]   [Full Text] [Related]  

  • 7. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
    Rummel MJ
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
    García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C
    Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
    Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
    Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
    Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
    J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
    Shimada K; Tomita A; Saito S; Kiyoi H
    Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649
    [No Abstract]   [Full Text] [Related]  

  • 14. [Toxicodermia by bendamustine: development of a desensization protocol].
    Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
    Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
    [No Abstract]   [Full Text] [Related]  

  • 15. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
    Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
    Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents for chronic lymphocytic leukemia.
    Wu M; Akinleye A; Zhu X
    J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
    Weide R; Pandorf A; Heymanns J; Köppler H
    Leuk Lymphoma; 2004 Dec; 45(12):2445-9. PubMed ID: 15621757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
    Ding W; Shanafelt TD; Lesnick CE; Erlichman C; Leis JF; Secreto C; Sassoon TR; Call TG; Bowen DA; Conte M; Kumar S; Kay NE
    Br J Haematol; 2014 Jan; 164(1):146-50. PubMed ID: 24111951
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
    Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.